Annual report pursuant to Section 13 and 15(d)

Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)

v3.3.1.900
Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2015
 [1]
Sep. 30, 2015
 [1]
Jun. 30, 2015
 [1]
Mar. 31, 2015
 [1]
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenues $ 48,183 $ 2,074 $ 2,539 $ 2,651 $ 4,347 $ 5,136 $ 5,973 $ 3,410 $ 55,447 $ 18,866 $ 35,451
United States [Member]                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenues                 10,685 11,756 19,955
Europe [Member]                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenues                 44,662 5,510 15,396
Asia Pacific [Member]                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenues                 $ 100 $ 1,600 $ 100
[1] In the fourth quarter of 2015, the total revenues include upfront and milestone payments relating to various out-licensing arrangements, including a $37.0 million upfront payment from Novartis, a $5.0 million upfront payment from Novo Nordisk and a $3.8 million payment from Pfizer.